Behcet's Disease
24
3
3
16
Key Insights
Highlights
Success Rate
94% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 40/100
4.2%
1 terminated out of 24 trials
94.1%
+7.6% vs benchmark
17%
4 trials in Phase 3/4
13%
2 of 16 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 16 completed trials
Clinical Trials (24)
Vasculitis Pregnancy Registry
Clinical Study of TA-650 in Patients With Behcet's Disease (BD) With Special Lesions
Drug Rediscovery for Rare Immune Mediated Inflammatory Diseases
Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Low-dose IL-2 Treatment on Behcet's Disease
Behçet and LDH/Albumin
Induction Therapy With Anti-TNFα vs Cyclophosphamide in Severe Behçet Disease
Induction of Regulatory t Cells by Low Dose il2 in Autoimmune and Inflammatory Diseases
The Role of Rosuvastatin on Vascular Involvement in Behçet's Disease
Immunogenetic Mechanisms in Behcet's Disease
VCRC Patient Contact Registry Patient-Reported Data Validation Study
Assessment of Central Sensitization, Neuropathic Pain, Sleep Quality and Daily Life Activities in Behcet's Disease
Special Investigation in Patients With Intestinal Behcet's Disease (All Case Investigation)
Evaluation of Fibromyalgia With Disease Activity and Clinical Findings in Women With Behçet's Disease
Journey of Patients With Vasculitis From First Symptom to Diagnosis
Interferon-alpha2a Versus Cyclosporin A for Severe Ocular Behcet's Disease (INCYTOB)
Anti IL-18 (GSK1070806) in Behcet's Disease
A Pilot Study of XOMA 052 in Familial Cold Autoinflammatory Syndrome / Muckle-Wells Syndrome and Behcet's Disease
Observational Study of the Genetic Architecture of Neutrophil-Mediated Inflammatory Skin Diseases
Impact of Vasculitis on Employment and Income